Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Business
AI & Semiconductor
Taiwan
China
World
Editorial
Home
ASC30
#
ASC30
About 3 search results
Sort by Date
Business
PR Newswire
Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada.
PR Newswire
2026-08-30 18:15
Ascletis
ASC30
GLP-1 receptor agonist
Business
PR Newswire
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist.
PR Newswire
2026-07-15 18:00
Ascletis
ASC30_48 FDC
ASC48
Business
PR Newswire
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG
PR Newswire
2026-06-08 08:10
Ascletis
ASC30
ASC39
